Small Ubiquitin-like Modifiers （SUMOs） are a family of small， related proteins that can be enzymatically attached to a target protein by a post-translational modification process termed sumoylation. Unlike ubiquitination， which targets proteins for degradation， sumoylation participates in a number of cellular processes， such as nuclear transport， transcriptional regulation， apoptosis， and protein stability. All SUMO proteins share the conserved ubiquitin domain and the C-terminal diglycine cleavage/attachment site. Human SUMO2， also known as Sentrin2 and SMT3B is synthesized as a 95 amino acid （aa）， 11 kDa propeptide that contains a two aa C-terminal prosegment， and an 18 aa N-terminal protein interacting region （aa 33 -50）. Following prosegment cleavage， the C-terminal glycine is enzymatically attached to a lysine on a target protein. Human SUMO2 shares 100% sequence identity to SUMO-2 from mouse. SUMO2 also has very high sequence homology to SUMO3 and SUMO4， 86 % and 85%， respectively. SUMO2 shares only 44% sequence identity to SUMO1.
序列
请咨询我们客服或者请查看品牌官方网站
来源宿主
大肠杆菌中重组表达
溶解建议
Sterile filtered colorless solution. The SUMO2 containing 20 mM Tris-HCl buffer （pH 8.0）
保存建议
Can be stored at +4C for 1 week. For long term storage ， below -20?C.
Please prevent freeze-thaw cycles.
